Amplyx was founded on a mission to develop a new class of antifungal medicine that would overcome the severe limitations of today’s therapy options.
With a proven management team and strong financial position—having raised a total of $51.5 million in venture capital and received more than $10 million in grants from the National Institutes of Health—Amplyx will enter clinical trials in 2016 for its novel drug candidate APX001.
The company is based in San Diego, with its research operations located at Johnson & Johnson Innovation, JLABS.